Millipore (U.K.) Ltd.February 27, 2020

FDA 483 - Millipore (U.K.) Ltd. - February 27, 2020

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Millipore (U.K.) Ltd.

Record Details

An FDA inspection of Millipore (U.K.) Ltd., a licensed bulk blood grouping reagent manufacturer in Livingston, United Kingdom, revealed two significant observations. The firm was cited for releasing licensed products before completing conformity tests, specifically regarding sodium azide content, and for failing to maintain adequate records to trace manufacturing steps, including unreviewed calculations and assessments in batch records.

Company: Millipore (U.K.) Ltd.
Inspection Date: February 27, 2020
Product Type: Biologics
Office: International Compliance Team
People: Nimmy Mathews (Regulatory Project Manager)
Prabhu P. Raju (Program Expert for Advanced Manufacturing )

Open in Dashboard

ID · ffe29c45-c2bf-4244-bbbe-054d2ab64edd